India Pharma Outlook Team | Friday, 22 August 2025
A contract development and manufacturing agreement has been signed between AnGes Inc. and Boehringer Ingelheim, a biopharmaceutical business involved in both human and animal health, for the drug ingredient of AnGes' experimental treatment for peripheral artery disease (PAD).
This significant event comes after AnGes announced on August 8, 2025, that it had completed clinical testing and intended to move forward with a biologics license application (BLA). AnGes also stated that final preparations for a supply agreement were in progress at that time. Now that Boehringer Ingelheim has signed a contract to research and manufacture the drug material for the product, the two businesses will keep working together to get regulatory approval and provide future patient access.
Ei Yamada, PhD, president & CEO, AnGes, says: “We proudly collaborate with Boehringer Ingelheim BioXcellence, one of the top manufacturers of drugs and biologics in the world, and look forward to our mutual efforts toward a successful FDA approval.” Further updates regarding the Chemistry, Manufacturing, and Controls (CMC) will be provided to the FDA along with a pre-BLA meeting in the near future.
Also Read: AIIMS Study Reveals High Rate of Catheter-Linked Infections in India
“At Boehringer Ingelheim BioXcellence, we are committed to leveraging our expertise in biologics manufacturing. Therefore, we support our partners with high-quality, reliable manufacturing services to help them reach key regulatory milestones, such as FDA BLA approval, and to bring innovative therapies to patients worldwide. We deeply value the opportunity to collaborate with AnGes on their journey toward product launch, and we look forward to contributing to the future success of this important partnership,” says Ute Lehmann, head of key account management and business development at Boehringer Ingelheim BioXcellence.